Ling Wang1,2, Jia Jiang3, Beihui Xue3, Jie Lin1, Xiaowei Ji1, Xiangwu Zheng3, Kun Tang1. 1. Department of Nuclear Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. 2. Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. 3. Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Abstract
Background: The purpose of this study was to evaluate the value of quantitative assessment of intratumoral 2-deoxy-2-[18F]fluoro-D-glucose (2-[18F]FDG) metabolic spatial distribution (Q-FMSD) in differentiating pulmonary lesions with high 2-[18F]FDG uptake. Methods: In this retrospective study, a total of 564 patients with pulmonary lesions who underwent 2-[18F]FDG positron emission tomography/computed tomography (PET/CT) examination were analyzed. The maximum standard uptake value (SUVmax) of the proximal (pSUVmax) and distal (dSUVmax) regions of the lesions were measured, respectively. Then, Q-FMSD was obtained by the ratio of pSUVmax to dSUVmax. The diagnostic performance and area under receiver operating characteristic curve (AUC) were compared between Q-FMSD and conventional PET/CT methods for the diagnosis of pulmonary lesions with high 2-[18F]FDG uptake. Results: The malignant tumors presented significantly higher Q-FMSD values than the benign lesions (1.11 vs. 0.94, P<0.001), which indicated that the 2-[18F]FDG uptake in the proximal region was significantly higher than that of distal region in malignant lesions when compared with benign ones. For distinguishing hypermetabolic pulmonary malignant and benign lesions, the sensitivity, specificity and accuracy of Q-FMSD were 96.9%, 83.2% and 92.7%, respectively. Compared with other traditional methods, Q-FMSD presented significantly higher specificity than visual PET/CT (61.8%, P<0.001), retention index (RI) (33.8%, P<0.001) and SUVmax (11.0%, P<0.001). The AUC of Q-FMSD was 0.920, which was obviously larger than that of the SUVmax (0.587, P<0.001), RI (0.701, P<0.001), and visual PET/CT (0.781, P<0.001). Conclusions: Q-FMSD provides a simply and quantitative indicator for differentiating hypermetabolic pulmonary lesions with higher diagnostic performance than conventional PET/CT methods. Therefore, Q-FMSD should be recommended as a new promising marker to improve the diagnostic performance of hypermetabolic pulmonary lesions in clinical practice. 2022 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Background: The purpose of this study was to evaluate the value of quantitative assessment of intratumoral 2-deoxy-2-[18F]fluoro-D-glucose (2-[18F]FDG) metabolic spatial distribution (Q-FMSD) in differentiating pulmonary lesions with high 2-[18F]FDG uptake. Methods: In this retrospective study, a total of 564 patients with pulmonary lesions who underwent 2-[18F]FDG positron emission tomography/computed tomography (PET/CT) examination were analyzed. The maximum standard uptake value (SUVmax) of the proximal (pSUVmax) and distal (dSUVmax) regions of the lesions were measured, respectively. Then, Q-FMSD was obtained by the ratio of pSUVmax to dSUVmax. The diagnostic performance and area under receiver operating characteristic curve (AUC) were compared between Q-FMSD and conventional PET/CT methods for the diagnosis of pulmonary lesions with high 2-[18F]FDG uptake. Results: The malignant tumors presented significantly higher Q-FMSD values than the benign lesions (1.11 vs. 0.94, P<0.001), which indicated that the 2-[18F]FDG uptake in the proximal region was significantly higher than that of distal region in malignant lesions when compared with benign ones. For distinguishing hypermetabolic pulmonary malignant and benign lesions, the sensitivity, specificity and accuracy of Q-FMSD were 96.9%, 83.2% and 92.7%, respectively. Compared with other traditional methods, Q-FMSD presented significantly higher specificity than visual PET/CT (61.8%, P<0.001), retention index (RI) (33.8%, P<0.001) and SUVmax (11.0%, P<0.001). The AUC of Q-FMSD was 0.920, which was obviously larger than that of the SUVmax (0.587, P<0.001), RI (0.701, P<0.001), and visual PET/CT (0.781, P<0.001). Conclusions: Q-FMSD provides a simply and quantitative indicator for differentiating hypermetabolic pulmonary lesions with higher diagnostic performance than conventional PET/CT methods. Therefore, Q-FMSD should be recommended as a new promising marker to improve the diagnostic performance of hypermetabolic pulmonary lesions in clinical practice. 2022 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Entities:
Keywords:
Fluorodeoxyglucose (18F); distribution; lung nodules; maximum standard uptake value (SUVmax); metabolic; positron emission tomography (PET/CT)
Authors: Helmut Huber; Marina Hodolic; Ingrid Stelzmüller; Rainer Wunn; Margit Hatzl; Franz Fellner; Bernd Lamprecht; Domenico Rubello; Patrick M Colletti; Michael Gabriel Journal: Nucl Med Commun Date: 2015-05 Impact factor: 1.690